These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 8720295)

  • 1. [Behavioral studies of KSG-504, a new CCK-A receptor antagonist].
    Yamazaki Y; Takeda H; Akahane M; Tsubaki A; Ajisawa Y
    Nihon Yakurigaku Zasshi; 1996 Jan; 107(1):21-31. PubMed ID: 8720295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effects of KSG-504, a new CCK-A receptor antagonist, on gallbladder and gastrointestinal functions].
    Yamazaki Y; Akahane M; Kobayashi M; Shinagawa K; Sugiura M; Ajisawa Y
    Nihon Yakurigaku Zasshi; 1996 Jan; 107(1):33-44. PubMed ID: 8720296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological profile of KSG-504, a new cholecystokinin-A-receptor antagonist.
    Yamazaki Y; Akahane M; Kobayashi M; Kitazawa M; Kurashina Y; Iizuka K
    Jpn J Pharmacol; 1993 Oct; 63(2):219-25. PubMed ID: 7506805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect of KSG-504, a new CCK-A-receptor antagonist, on experimental acute pancreatitis in rats and mice].
    Kobayashi M; Shinagawa K; Sugiura M; Nagasawa T; Akahane M; Ajisawa Y
    Nihon Yakurigaku Zasshi; 1996 Apr; 107(4):183-95. PubMed ID: 8690301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of KSG-504, a new cholecystokinin-A-receptor antagonist, on pancreatic exocrine and endocrine secretions in rats.
    Yamazaki Y; Akahane M; Kobayashi M; Takeda H; Ajisawa Y
    Jpn J Pharmacol; 1996 Feb; 70(2):183-90. PubMed ID: 8866756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new CCK-A antagonist, KSG-504, administered intraduodenally, inhibits pancreatic secretion in rats.
    Moriyoshi Y; Shiratori K; Takeuchi T; Watanabe S
    Pancreas; 1994 Mar; 9(2):225-9. PubMed ID: 8190724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cholecystokinin-A specific antagonism of KSG-504 to cholecystokinin receptor binding and pancreatic secretion in mammals.
    Yamazaki Y; Shinagawa K; Takeda H; Kobayashi M; Akahane M; Ajisawa Y
    Jpn J Pharmacol; 1995 Dec; 69(4):367-73. PubMed ID: 8786640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different inhibitory effects of the newly developed CCK receptor antagonists FK480 and KSG-504 on pancreatic exocrine and endocrine secretion in the isolated perfused rat pancreas.
    Kihara Y; Otsuki M
    Pancreas; 1995 Mar; 10(2):109-17. PubMed ID: 7716133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of KSG-504, a new synthetic cholecystokinin receptor antagonist on ethionine-induced acute pancreatitis in rats].
    Okumura Y; Bamba T; Shintani Y; Yoshioka U; Inoue H; Fujiyama Y; Hosoda S
    Nihon Shokakibyo Gakkai Zasshi; 1993 Dec; 90(12):3032-40. PubMed ID: 8283814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of short-term administration of the CCK receptor antagonist, KSG-504, on regeneration of pancreatic acinar cells in acute pancreatitis in rats.
    Okumura Y; Inoue H; Fujiyama Y; Bamba T
    J Gastroenterol; 1995 Aug; 30(4):493-9. PubMed ID: 7550860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of a new cholecystokinin receptor antagonist (KSG 504) on the early stage of the healing process in acute pancreatitis induced in rats by the closed duodenal loop technique.
    Ha S; Satake K; Hiura A; Sowa M; Nishiwaki H
    Pancreas; 1994 Jul; 9(4):501-7. PubMed ID: 7524065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytokine level changes in L-arginine-induced acute pancreatitis in rat.
    Takács T; Czakó L; Jármay K; Farkas G; Mándi Y; Lonovics J
    Acta Physiol Hung; 1996; 84(2):147-56. PubMed ID: 9046361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antagonists of central and peripheral behavioral actions of cholecystokinin octapeptide.
    Crawley JN; Stivers JA; Hommer DW; Skirboll LR; Paul SM
    J Pharmacol Exp Ther; 1986 Feb; 236(2):320-30. PubMed ID: 3003339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypolocomotion induced by peripheral or central injection of CCK in the mouse is blocked by the CCKA receptor antagonist devazepide but not by the CCKB receptor antagonist L-365,260.
    O'Neill MF; Dourish CT; Iversen SD
    Eur J Pharmacol; 1991 Feb; 193(2):203-8. PubMed ID: 2050197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of dexloxiglumide and spiroglumide, two new CCK-receptor antagonists, on gastric emptying and secretion in the rat: evaluation of their receptor selectivity in vivo.
    Scarpignato C; Kisfalvi I; D'Amato M; Varga G
    Aliment Pharmacol Ther; 1996 Jun; 10(3):411-9. PubMed ID: 8791971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Satiety induced by endogenous and exogenous cholecystokinin is mediated by CCK-A receptors in mice.
    Weatherford SC; Chiruzzo FY; Laughton WB
    Am J Physiol; 1992 Apr; 262(4 Pt 2):R574-8. PubMed ID: 1566921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of CCK antagonists on CCK-induced suppression of locomotor activity in mice.
    Hirosue Y; Inui A; Miura M; Nakajima M; Okita M; Himori N; Baba S; Kasuga M
    Peptides; 1992; 13(1):155-7. PubMed ID: 1620653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo pharmacology of L-364,718, a new potent nonpeptide peripheral cholecystokinin antagonist.
    Lotti VJ; Pendleton RG; Gould RJ; Hanson HM; Chang RS; Clineschmidt BV
    J Pharmacol Exp Ther; 1987 Apr; 241(1):103-9. PubMed ID: 2437282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological profile of FK480, a novel cholecystokinin type-A receptor antagonist: comparison to loxiglumide.
    Ito H; Sogabe H; Nakarai T; Sato Y; Tomoi M; Kadowaki M; Matsuo M; Tokoro K; Yoshida K
    J Pharmacol Exp Ther; 1994 Feb; 268(2):571-5. PubMed ID: 7509389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurobehavioural effects of SR 27897, a selective cholecystokinin type A (CCK-A) receptor antagonist.
    Poncelet M; Arnone M; Heaulme M; Gonalons N; Gueudet C; Santucci V; Thurneyssen O; Keane P; Gully D; Le Fur G
    Naunyn Schmiedebergs Arch Pharmacol; 1993 Jul; 348(1):102-7. PubMed ID: 8397341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.